Screener
AOCI at other companies
Other financials
Where this comes from
Reported directly by Revolution Medicines, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax.
The source filing: Revolution Medicines, Inc.’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 4:10 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-335104
FAQ
- What is Revolution Medicines, Inc.'s AOCI?
- Revolution Medicines, Inc. (RVMD) reported AOCI of -$5.95M in Q2 2026.
- How has Revolution Medicines, Inc.'s AOCI changed year-over-year?
- Revolution Medicines, Inc.'s AOCI decreased by 557.0% year-over-year, from $1.3M to -$5.95M.
- What is the long-term trend for Revolution Medicines, Inc.'s AOCI?
- Over 5 years (2020 to 2025), Revolution Medicines, Inc.'s AOCI has grown at a 94.6% compound annual growth rate (CAGR), from $116K to $3.24M.
- What does AOCI mean?
- Accumulated gains and losses bypassing the income statement — unrealized investment gains/losses, currency translation, pension adjustments, and hedge results.
Ask your AI about Revolution Medicines, Inc.'s aoci.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude